Virtual Pharma Manufacturing: Beyond Spreadsheets and Emails

The Growing Challenges of Virtual Pharmaceutical Manufacturing

The virtual pharmaceutical business model has significantly changed how biotechnology and pharmaceutical companies develop and bring new therapies to market. Rather than investing in their own manufacturing facilities and infrastructure, many organizations rely on Contract Manufacturing Organizations (CMOs) to handle production activities. This approach allows pharmaceutical companies to minimize capital investments, take advantage of specialized manufacturing capabilities, and dedicate more resources to drug development and commercialization.

Although outsourcing manufacturing offers several advantages, it also creates operational challenges, especially when it comes to maintaining accurate information and coordinating activities between pharmaceutical companies and their manufacturing partners.

Many virtual pharma organizations still depend heavily on spreadsheets, email communications, and shared documents to manage inventory, monitor manufacturing progress, and exchange critical information with their CMOs.

During the early stages of clinical development, these familiar tools may provide an adequate means of communication and coordination. However, as clinical programs advance, manufacturing operations become more complex, and regulatory expectations increase, managing these activities through disconnected systems becomes increasingly difficult.

The real challenge extends beyond sharing information. Virtual pharma organizations need confidence that the information they receive is accurate, up to date, properly documented, and readily available when needed.

1. The Problem with Multiple Sources of Truth

One of the greatest challenges with spreadsheet-based collaboration is the creation of multiple sources of truth.

Consider a virtual pharmaceutical organization working with a CMO responsible for manufacturing its drug product. The pharma organization maintains an internal inventory spreadsheet, while the CMO tracks materials in a separate system. Updates are exchanged through email with multiple recipients, and additional spreadsheets are created to reconcile discrepancies.

Before long, multiple versions of the same information exist across different systems and individuals’ inboxes.

This fragmented approach creates operational risks:

Inconsistent inventory information: The virtual pharma organizations’ records may not reflect actual quantities held by the CMO.
Time-consuming data reconciliation: Employees often spend unnecessary time reviewing spreadsheets, identifying discrepancies, and manually correcting information across different systems.
Delays in decision-making: Without immediate access to reliable inventory and manufacturing data, management may struggle to make informed purchasing and production decisions.
Increased risk of errors: Manually entering and updating information across multiple documents creates more opportunities for mistakes and inconsistencies.

As virtual pharma organizations grow and manufacturing activities become more involved, keeping information accurate and consistent across separate systems requires considerably more time and effort.

2. Emails Are Communication Tools, Not Manufacturing Management Systems

Email plays an important role in day-to-day business communications, but it is not intended to replace a dedicated manufacturing or inventory management solution.

For virtual pharma organizations, important manufacturing and inventory information is often scattered across email threads, file attachments, and individual employee inboxes. As a result, locating the most recent or accurate information can become a frustrating and time-consuming process.

Even a straightforward question about available inventory may involve multiple emails between the pharmaceutical organization, its CMO, procurement personnel, and quality teams before everyone can agree on the correct figures.

These challenges become even more apparent when employees transition into different roles or leave the company. Important conversations, supporting documentation, and previous decisions may be difficult to retrieve, particularly when they were never entered into a centralized system.

Relying on email to coordinate manufacturing activities also makes it harder to track responsibilities, monitor outstanding tasks, and maintain clear documentation of approvals and decisions.

While email provides a record of conversations, it does not offer the controls, accountability, or traceability required to effectively manage pharmaceutical manufacturing operations.

Virtual pharma organizations benefit from having defined processes and a centralized environment where manufacturing information can be recorded, updated, and accessed by authorized personnel. This helps improve coordination with CMOs while providing greater confidence in the accuracy and availability of critical operational information.

3. Regulatory Compliance and Data Integrity Concerns

Pharmaceutical manufacturing operates in a highly regulated environment where data integrity, traceability, and documentation are essential.

FDA 21 CFR Parts 210 and 211 establish Current Good Manufacturing Practice (CGMP) requirements, while 21 CFR Part 11 addresses applicable electronic records and electronic signatures.

Although spreadsheets and emails are not inherently prohibited, using them for GxP-relevant activities requires appropriate controls.

Spreadsheets and exchanged emails show a clear lack of control and pose a tremendous risk to compliance:

Who created, modified, or approved a controlled record.
The timestamp of when changes were made and why.
Whether appropriate access restrictions and controls were maintained.
Whether records are complete, accurate, and protected from unauthorized modification.
Whether records can be retrieved during regulatory inspections. The actual record and the associated audit trail.

These concerns become particularly important when records are accessed by many organizations and individuals that participate in the manufacturing process.

Virtual pharma organizations, in most cases, outsource their manufacturing activities, but the quality processes of the CMO is the responsibility of the pharma organization.

The principles of ALCOA+—emphasizing attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available data—provide an important framework for managing manufacturing information.

4. How Limited CMO Inventory Visibility Impacts Supply Chains

For virtual pharmaceutical organizations, tracking inventory becomes more complicated when raw materials, intermediates, and finished products are managed at external CMO facilities.

Many companies rely on inventory updates from their CMOs, which may be provided weekly, monthly, or upon request. Unfortunately, inventory levels can change between reporting periods, leaving organizations to make decisions based on outdated information.

Without reliable visibility into inventory, organizations may experience:

Unexpected shortages of critical raw materials.
Unnecessary purchasing and excess inventory.
Disruptions to manufacturing schedules.
Difficulty tracking material expiration and retest dates.
Time-consuming inventory reconciliation across CMO locations.
Challenges forecasting future material needs.

For example, a pharmaceutical company may schedule a manufacturing run based on an inventory report indicating sufficient API is available. However, if some of that material has since been consumed, the resulting shortage could delay production and create unexpected costs.

These challenges are particularly significant when managing expensive APIs, temperature-sensitive materials, or products with limited shelf lives.

Having access to more current inventory information allows virtual pharma organizations to identify potential shortages earlier, better coordinate material requirements, and make more informed supply chain decisions.

5. Scaling Manufacturing Without Increasing Administrative Burden

During early clinical development, a virtual pharmaceutical company may work with one CMO and manage relatively limited manufacturing activity.

As the organization progresses through clinical trials and prepares for commercialization, operational complexity increases.

Additional manufacturing partners may be introduced, production volumes grow, and more materials and transactions require oversight.

Processes that worked during Phase 1 or Phase 2 may become inefficient as organizations advance toward Phase 3 and commercial manufacturing.

Without structured systems, companies may need additional personnel simply to manage information exchanges, reconcile spreadsheets, and coordinate activities across manufacturing partners.

The objective should be to reduce manual activities and establish consistent processes that support growth without proportionally increasing administrative overhead.

6. Improving Virtual Pharma Manufacturing with Connected Systems

Addressing these challenges requires moving from disconnected spreadsheets and emails toward centralized, controlled information management.

Modern pharmaceutical ERP platforms and collaboration portals can provide a shared environment where virtual pharma organizations and CMOs exchange information through defined workflows.

Benefits include:

Centralized information: A consistent source for inventory and manufacturing data.
Improved visibility: Timely access to information across manufacturing partners.
Controlled access: Role-based permissions protecting sensitive information.
Greater traceability: Documented transactions and audit trails.
Reduced manual processes: Less duplicate data entry and reconciliation.
Improved collaboration: More efficient coordination between pharma organizations and CMOs.

Importantly, a connected solution does not necessarily require CMOs to replace their existing manufacturing systems. Integration capabilities and collaboration portals can facilitate information sharing while allowing partners to maintain established processes.

7. How Slingshot Pharma Helps Bridge the Gap

Recognizing these challenges, Slingshot Pharma has developed a CMO Portal designed to improve collaboration and information sharing between pharmaceutical organizations and their contract manufacturing partners.

Built around Slingshot Pharma's configurable, pharma-focused ERP platform, the CMO Portal supports a more structured approach to managing information exchanged between organizations.

Rather than relying on disconnected spreadsheets, email attachments, and manually reconciled reports, virtual pharma companies can benefit from:

Improved Inventory Visibility: Better access to information regarding inventory and material movements associated with external manufacturing partners.
Reduced Manual Processes: More structured information exchanges that minimize repetitive administrative tasks and potential errors.
Enhanced Data Control: Slingshot Pharma's ERP platform supports role-based access, audit trails, and electronic signatures to help organizations manage regulated information.
Scalability: A configurable ERP foundation designed to support expanding manufacturing networks and increasingly complex supply chain requirements.

By connecting internal operations with external manufacturing activities, Slingshot Pharma helps organizations improve coordination while maintaining greater control over their information.

Conclusion: Moving Beyond Spreadsheets and Emails in Pharma Manufacturing

Spreadsheets and emails will always have a place in pharmaceutical operations. However, relying on them as the primary means of managing outsourced manufacturing creates growing challenges involving data accuracy, regulatory compliance, inventory visibility, and operational efficiency.

As virtual pharmaceutical organizations move from clinical development toward commercialization, structured collaboration with contract manufacturers becomes increasingly important.

Slingshot Pharma's ERP software and CMO Portal provide a more connected approach to virtual pharmaceutical manufacturing, helping organizations improve visibility, traceability, and collaboration with their manufacturing partners.

For virtual pharma companies looking to scale without sacrificing operational control, moving beyond disconnected spreadsheets and emails is an important step toward long-term success.

Ready to Move Beyond Spreadsheets and Emails?

Discover how Slingshot Pharma's CMO Portal can help improve collaboration with your contract manufacturers, increase operational visibility, and reduce administrative complexity.

Request a Demo to learn more.

‍

Customer Connection

Why Spreadsheets and Emails Are No Longer Enough for Virtual Pharma Manufacturing